# A Clinical Trial of P134 Cells in Recurrent Glioblastoma

> **NCT07318818** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 26 (estimated)

## Conditions studied

- Recurrent Glioblastoma IDH Wildtype

## Interventions

- **BIOLOGICAL:** P134 cell injection

## Key facts

- **NCT ID:** NCT07318818
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-08-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318818, "A Clinical Trial of P134 Cells in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07318818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*